Wanbury FY26 PAT Surges 117% YoY to ₹66.1 Cr; EPS Doubles to ₹20.55
Wanbury Limited reported FY26 PAT surge of 117% YoY to ₹66.1 Cr and EPS doubling to ₹20.55. EBITDA grew 34.9% YoY to ₹107.7 Cr. The company launched a new Anaesthetic API and received zero observation from MFDS, Korea inspection. Q4 FY26 PAT grew 7.2% YoY to ₹21.7 Cr.
The substantial YoY growth in PAT and EPS, coupled with successful new product launches and regulatory clearances, indicates a strong positive impact on the company's financial health and future prospects.
The company reported significant year-on-year growth in PAT and EPS, alongside strong EBITDA growth and operational achievements like new API launches and regulatory approvals, indicating positive business performance.
Wanbury Limited announced its audited financial results for the fourth quarter and full year ended March 31, 2026.
For the full year FY26, the company reported a significant surge in Profit After Tax (PAT) by 117% year-on-year (YoY) to ₹66.1 crore, with the PAT margin expanding by 509 basis points to 10.2%. Earnings Per Share (EPS) more than doubled from ₹9.32 in FY25 to ₹20.55 in FY26. EBITDA grew by 34.9% YoY to ₹107.7 crore, attributed to revenue growth, a favorable product mix, better yields, procurement efficiencies, and process optimization. The gross margin for Q4 FY26 expanded by 887 basis points YoY to 60.4%, despite a revenue impact from the West Asia crisis in March 2026.
Operationally, Wanbury launched a new Anaesthetic API from its Tanuku facility, with commercial dispatches to Europe commencing in February 2026. The company is strengthening its pipeline with upcoming specialty APIs including Dextromethorphan HBr, Rivaroxaban, and Sitagliptin. Significant regulatory milestones include zero observations in MFDS, Korea inspection (April 2026), USFDA inspection at Patalganga, and ANVISA Brazil inspection. ANVISA, Brazil also approved Sertraline Form II, enhancing regulated market access. The formulations business showed improved performance with new launches.
In Q4 FY26, revenue from operations was ₹164.6 crore, a decrease of 4.3% YoY, impacted by the West Asia crisis disrupting API export dispatches in March. However, gross margin increased 11.1% YoY to ₹99.5 crore. PAT for the quarter stood at ₹21.7 crore, a growth of 7.2% YoY, even after absorbing a one-time exceptional charge of ₹3.6 crore related to the implementation of new labor codes. PAT margin improved by 150 bps YoY to 13.2% in Q4 FY26.
Mr. Mohan Rayana, Director, Wanbury Limited, stated that FY26 was an important year for strengthening business fundamentals through operational efficiencies and portfolio expansion. He highlighted the successful launch of the new Anaesthetic API and clearing the MFDS, Korea inspection as key milestones. The company plans to continue its API growth journey in FY27 with new launches and a strong pipeline.
What to do with a filing like this
Wanbury Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Wanbury Limited. Read the original for the full detail.